All Poppy Morgan of San Francisco wanted was to see her husband, Ted, reflected in their child's face. Unfortunately, for many years, this could not be a reality. Ted was HIV positive, and Poppy could not find a way to conceive safely. After many disappointments, including a brief hope for sperm washing that was quickly dashed, Poppy found pre-exposure prophylaxis (PrEP).
26 November 2014 | The Body
Americans have developed a cultural relationship to risk. We like to tell ourselves that we deserve the calamities that befall us.
20 November 2014 | Medium
Those of you who have read my blog know that I am on pre-exposure prophylaxis (PrEP) to reduce my risk for HIV infection. And more and more of my patients are also beginning to take Truvada (a pill combining the antiretroviral drugs tenofovir and emtricitabine) as PrEP to prevent HIV infection. And all of my patients are asking me what my recommendations are for condom use in light of the data on PrEP.
17 November 2014 | TheBody.com
By now, many of you may have seen the headlines or read news about what sounds like encouraging results, announced in late October, about two clinical trials of PrEP (pre-exposure prophylaxis) in gay and bisexual men. It's important, however, to not make assumptions based on the preliminary findings about the PROUD and IPERGAY studies.
17 November 2014 | Huffington Post
Michael Weinstein of the AIDS Healthcare Foundation shows up in lots of news articles about Truvada in part because he runs a large H.I.V.-care organization, and in part because he gives colorful quotes. But he also shows up because he and the foundation stand more or less alone within the world of H.I.V.-prevention groups in their skepticism about PrEP.
17 November 2014 | New York Times
In a recent BMJ Blog Dr Rupert Whitaker cast a critical eye on Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV infection, questioning its role as a public health intervention. The piece is challenging and although it rightly emphasises the need for a carefully planned implementation, it contains a number of factual inaccuracies and conceptual misunderstandings that need to be addressed.
PROUD pilot study interim analysis finds pre-exposure prophylaxis (PrEP) is highly protective against HIV
Pre-Exposure Prophylaxis: The Great Confusion
WHO recommends PrEP for MSM: Time for the UK to take note and act?
14 November 2014 | Incidence 0
What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options.
14 November 2014 | Science Speaks
Taking Truvada changed my life. No, really.
12 November 2014 | The Stranger
On the heels of news that gay men had very high levels of protection from HIV infection through intermittent pre-exposure prophylaxis (PrEP) timed around sexual activity, a mathematical model predicts that most women would need to stick with a daily dose of Truvada (tenofovir/emtricitabine) to prevent HIV infection from vaginal sex.
12 November 2014 | The Body Pro
The results of the PROUD study will renew calls for the intervention to be made available in the UK. Further study is needed to confirm the wider acceptability of PrEP to the highest risk individuals and how it affects risk behaviour, but the UK health authorities should begin now to look into how best to deploy this intervention. The numbers show that a new approach to curbing the HIV epidemic in the UK's MSM is needed, the approach exists, and should be made available as soon as possible.
10 November 2014 | The Lancet HIV